COMPANY PROFILE

Inspirna

Explore full profile

Biotechnology company developing drugs for the treatment of cancer

New York City, United StatesFounded 2010Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2022

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Inspirna

Rgenix, operating under the name Inspirna, is a biotech startup that focuses on developing innovative treatments for common, previously untreatable cancers. The company's primary approach is to identify new drivers of cancer metastasis, which are the factors that cause cancer to spread within the body. They do this through their proprietary RNA-DRIVEr™ platform and microRNA mapping. The RNA-DRIVEr™ platform is a clinically-validated tool that helps to discover previously unknown factors that drive cancer growth and spread.

Read full description

Inspirna's business model revolves around the development and commercialization of small molecules and biologics, which are types of drugs used in cancer treatment. The company's main clients are patients suffering from common cancers, particularly colorectal and non-small cell lung cancer.

Inspirna's revenue comes from the development and sale of these drugs. Currently, the company has two drugs in the pipeline. The first, ompenaclid (RGX-202), is in Phase 2 development for patients with RAS mutant colorectal cancer. The second, abequolixron (RGX-104), is in Phase 1b/2 development for patients with non-small cell lung cancer and endometrial cancer.

Inspirna's goal is to make cancer a manageable, chronic condition by providing more practical treatment options that prolong survival without decreasing patients’ quality of life. The company aims to develop medicines with oral dosing and safety profiles that can easily be incorporated into existing standard-of-care treatments.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: New York City, United States
Employees: 8
Open positions: None listed
Dealroom signal: 61.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Intellectual Property, Risk Management, Biotechnology, Oncology, Drug Development, DNA, Surgery, Genetics and genomics, Antibodies, Immune System
Business model: Manufacturing
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Inspirna.

See all news

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES DOther financing	Jul 2022	$50M	$200M	Dreavent 6 · Novo Holdings · Vivo Capital · The New York City Investment Fund	↗
SERIES COther financing	Oct 2018	$40M	$160M	Sofinnova Partners · Partnership Fund for New York City · WuXi AppTec · Novo Holdings	—

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Inspirna website traffic

Latest recorded traffic for Inspirna is 180 monthly website visits, down 82% over the last three months. Inspirna's team declined 38.5% over the past year.

Latest monthly visits180 3-month web change-82% 1-year team growth-38.5%

Monthly website visitsApr 2016–Mar 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RERepairogenRepairogen employs proprietary DNA-repair technologies to create advanced, scientifically-proven skincare products	New York City, United States	Operational	2	$1.5M	$4M
HTHiFiBiO TherapeuticsAn emerging clinical stage multinational company mobilizing the human immune system to treat cancer and autoimmune diseases	Cambridge, United States	Operational
SBScenic BiotechGenetic modifier therapies for rare inherited diseases	Amsterdam, Netherlands	Operational
SCScancellClinical-stage immunotherapies for difficult-to-treat cancers	Oxford, United Kingdom	Operational
OGOryzon GenomicsDevelops diagnostic and therapeutic tools	Cornellà de Llobregat, Spain	Operational
TOToxysProvides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development	Leiden, Netherlands	Operational
ALAlectorCombining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel	San Francisco, United States	Operational
KGKailos GeneticsConsumers access to affordable physician-ordered genetic tests	Huntsville, United States	Acquired